logo
logo
DGX stock ticker logo

Quest Diagnostics Incorporated

NYSE•DGX
CEO: Mr. James E. Davis
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1996-12-17
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
連絡先情報
500 Plaza Drive, Secaucus, NJ, 07094, United States
973-520-2700
www.questdiagnostics.com
時価総額
$23.19B
PER (TTM)
23.3
31.5
配当利回り
1.5%
52週高値
$213.50
52週安値
$157.20
52週レンジ
91%
順位24Top 10.8%
5.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$2.81B+0.00%
直近4四半期の推移

EPS

$2.21+0.00%
直近4四半期の推移

フリーCF

$307.00M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Strong Revenue and Income Growth Total net revenues reached $11.04B USD, growing 11.8%. Net income attributable to Quest Diagnostics was $992M USD, up 13.9%.
Advanced Diagnostics Revenue Milestone Advanced Diagnostics offerings generated over $1B USD in 2025 revenues, achieving double-digit growth across key clinical areas.
Operating Efficiency Improvements Operating income grew 15.6% to $1.56B USD, supported by Invigorate program savings offsetting inflationary pressures.
Capital Return Commitment Board authorized $1B increase to share repurchase program; quarterly dividend raised 7.5% to $0.86 per share.

リスク要因

Reimbursement Rate Uncertainty Ongoing PAMA uncertainty and government payer efforts to reduce utilization and reimbursement pose material risks to revenue stability.
Competitive Testing Internalization Competition intensifies from hospital-affiliated labs and providers internalizing testing, potentially reducing outreach volume and pricing power.
Inflationary Cost Pressures Rising costs for labor, benefits, testing equipment, and supplies pressure margins despite Invigorate cost savings efforts.
Cybersecurity and IT System Risks Reliance on IT systems exposes operations to cyberattacks, data breaches, and potential disruption from Project Nova modernization.

見通し

Modernizing Order to Cash Committed to multi-year Project Nova to modernize IT infrastructure, expecting completion in 2031 to 2032 for streamlined operations.
Strategic Capital Investment Focus Estimate $550M capital expenditure in 2026 for lab equipment, automation, and technology supporting diagnostic offerings growth.
Continued Advanced Testing Focus Strategy emphasizes growing Advanced Diagnostics, including oncology monitoring via Haystack Oncology MRD test commercialization.
Maintaining Strong Liquidity Expect sufficient cash flow and $1.3B borrowing capacity to fund operations, acquisitions, and debt obligations through 2026.

同業比較

売上高 (TTM)

THC stock ticker logoTHC
$21.31B
+3.1%
LH stock ticker logoLH
$13.95B
+7.2%
DGX stock ticker logoDGX
$11.04B
+11.8%

粗利益率 (最新四半期)

GMAB stock ticker logoGMAB
92.3%
-0.7pp
INCY stock ticker logoINCY
90.9%
+1.8pp
UTHR stock ticker logoUTHR
86.9%
-1.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
NTRA$28.31B-133.4-15.3%8.5%
BIIB$27.88B21.57.3%23.6%
MTD$26.28B30.2-487.2%63.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.9%
緩やかな成長
4四半期純利益CAGR
3.7%
収益性の緩やかな改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年4月20日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし